EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review

Kathryn F. Mileham; Edward S. Kim; William N. William

doi:10.1002/9781118468791.ch26

EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review

Kathryn F. Mileham, Edward S. Kim, William N. William

Thoracic Head & Neck Medical Oncology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Epidermal growth factor receptor (EGFR)-targeted agents have been extensively evaluated for management of recurrent/metastatic nonsmall cell lung cancers. Clinical trials utilizing EGFR tyrosine kinase inhibitors and antibodies have been completed in the frontline setting, as well as in the settings of maintenance and salvage therapy. In this chapter, the results of the main studies on this topic will be reviewed. Novel strategies related to targeting the EGFR axis will also be discussed.

Original language	English (US)
Title of host publication	Lung Cancer
Subtitle of host publication	Fourth Edition
Publisher	Wiley-Blackwell
Pages	406-420
Number of pages	15
ISBN (Electronic)	9781118468791
ISBN (Print)	9781118468746
DOIs	https://doi.org/10.1002/9781118468791.ch26
State	Published - May 27 2014

Keywords

Antibody
Cetuximab
Clinical trials
Epidermal growth factor receptor
Erlotinib
Gefitinib
Nonsmall cell lung cancer
Tyrosine kinase inhibitor

ASJC Scopus subject areas

General Medicine

Access to Document

10.1002/9781118468791.ch26

Cite this

@inbook{5ba81af25a8b48b09710cc49aea209c6,

title = "EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review",

abstract = "Epidermal growth factor receptor (EGFR)-targeted agents have been extensively evaluated for management of recurrent/metastatic nonsmall cell lung cancers. Clinical trials utilizing EGFR tyrosine kinase inhibitors and antibodies have been completed in the frontline setting, as well as in the settings of maintenance and salvage therapy. In this chapter, the results of the main studies on this topic will be reviewed. Novel strategies related to targeting the EGFR axis will also be discussed.",

keywords = "Antibody, Cetuximab, Clinical trials, Epidermal growth factor receptor, Erlotinib, Gefitinib, Nonsmall cell lung cancer, Tyrosine kinase inhibitor",

author = "Mileham, {Kathryn F.} and Kim, {Edward S.} and William, {William N.}",

year = "2014",

month = may,

day = "27",

doi = "10.1002/9781118468791.ch26",

language = "English (US)",

isbn = "9781118468746",

pages = "406--420",

booktitle = "Lung Cancer",

publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies

T2 - Clinical Trial Review

AU - Mileham, Kathryn F.

AU - Kim, Edward S.

AU - William, William N.

PY - 2014/5/27

Y1 - 2014/5/27

N2 - Epidermal growth factor receptor (EGFR)-targeted agents have been extensively evaluated for management of recurrent/metastatic nonsmall cell lung cancers. Clinical trials utilizing EGFR tyrosine kinase inhibitors and antibodies have been completed in the frontline setting, as well as in the settings of maintenance and salvage therapy. In this chapter, the results of the main studies on this topic will be reviewed. Novel strategies related to targeting the EGFR axis will also be discussed.

AB - Epidermal growth factor receptor (EGFR)-targeted agents have been extensively evaluated for management of recurrent/metastatic nonsmall cell lung cancers. Clinical trials utilizing EGFR tyrosine kinase inhibitors and antibodies have been completed in the frontline setting, as well as in the settings of maintenance and salvage therapy. In this chapter, the results of the main studies on this topic will be reviewed. Novel strategies related to targeting the EGFR axis will also be discussed.

KW - Antibody

KW - Cetuximab

KW - Clinical trials

KW - Epidermal growth factor receptor

KW - Erlotinib

KW - Gefitinib

KW - Nonsmall cell lung cancer

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84927144249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927144249&partnerID=8YFLogxK

U2 - 10.1002/9781118468791.ch26

DO - 10.1002/9781118468791.ch26

M3 - Chapter

AN - SCOPUS:84927144249

SN - 9781118468746

SP - 406

EP - 420

BT - Lung Cancer

PB - Wiley-Blackwell

ER -

EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this